



THE PROBLEM



The prevalence of **blood disorders** is **increasing globally**. The diagnostic and monitoring methods for these diseases are long, inefficient and present a lot of drawbacks for the patients. **Transfusions** are **used as treatment** for different hematologic diseases. There is **no specific method** to **control** the **number** of required **transfusions** as well as their **efficiency**.

 **80M** people suffer a blood disorder in Europe

 **23b€** globally/ year healthcare costs of blood disorders

 **112M** transfusions / year

 **20%** transfusions are unnecessary

 **4b€** extra cost for healthcare system

THE SOLUTION



RheoDx technology has been developed at Centre for Mathematical Research and is based on the study of blood's physical properties. The obtained data is cloud - processed, and associated with precision to blood cell pathologies through pattern recognition.

- Able to evaluate the wide range of hematologic pathologies that are treated with transfusions.
- Helps in the determination of transfusional needs.
- Diagnostic of Hemolytic Anemias.

KEY BENEFITS



VERSATILE: Applicable to multiple hematologic conditions



PORTABLE: point-of-care or over-the-counter



PRECISE: Single blood drop required




FAST: Result in **5 minutes**


MILESTONES

- 2018 **Foundation**
- 2018 **Proof of Concept**
- 2018 **Patent Protection** (EU & USA)
- 2019 **Preclinical Validation**
- 2020 **Clinical Validation**
- 2021 **CE Mark**
- 2021 **Market Launch as IVD Device**

FUNDS RAISED



FUNDING GOALS



KEYMETRICS

- 0,5€** Production cost
- 1** Blood drops needed
- 5 min / test**
- 8€** RheoDx Test price
- 60 bn \$** Global IVD Market
- x7** Potential ROI (Exit 2020 – 2023)

ACCELERATION PROGRAMS

- IMAGINE(F) (2019)
- IQS NEXT TECH THE INDUSTRIAL ACCELERATOR (2018)
- eit Health Bioentrepreneur bootcamp (2018)
- The COLLIDER A programme of MOBILE WORLD CAPITAL BARCELONA (2017)

MANAGING TEAM



Oliver Balcells
CEO




Samantha López
CSO




Aurora Hernández, PhD
R&D Strategy Owner


PROMOTER

FUNDACIÓN LEITAT

WITH THE SUPPORT OF

Generalitat de Catalunya
Departament de Salut

Agència de Qualitat i Avaluació Sanitàries de Catalunya

Obra Social "la Caixa"